

PRESS MAILING

at this paper and every paper referred to therein as being enclosed is being deposited with the U.S. Postal Service as express mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below

Express Mail Label No. EV596387667 US

Attorney Docket No. 100717-502 / Bayer 10,139.3 KGB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

Thomas KRAHN et al

SERIAL NO.

09/966,522

CUSTOMER NO.:

27384

FILED

September 28, 2001

FOR

MASKING BACKGROUND FLUORESCENCE AND

LUMINESCENCE IN THE OPTICAL ANALYSIS OF BIOMEDICAL

ASSAYS

ART UNIT

1641

EXAMINER

Pensee T. Do

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO/SB/08.

I. Timeliness, Fees and Certifications in lieu of Fees

This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the

USSN 09/966,522

mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

- B. This information disclosure statement is being filed after the period in A above, but before the mailing of either a final action or a notice of allowance. Pursuant to 37 CFR § 1.97(c), consideration of this information disclosure statement requires a fee or a statement under 37 CFR § 1.97(e):
 - 1. The Assistant Commissioner is hereby authorized to charge the fee set forth in 37 CFR § 1.17(p) to Deposit Account No. 14-1263.
 - 2. Applicants hereby state that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.
 - ☐ 3. Applicants hereby state that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR § 1.56 more than three months prior to the filing of this information disclosure statement.
- C. This information disclosure statement is being filed after the period specified in B above, but on or before the payment of the issue fee. Pursuant to 37 CFR § 1.97(d), consideration of this information disclosure statement requires a petition, which Applicants hereby request, and payment of the petition fee, which is set forth in 37 CFR § 1.17(i), and which the Assistant Commissioner is hereby authorized to charge to Deposit Account No. 14-1263. Consideration of this information disclosure statement also requires a statement under 37 CFR § 1.97(e):

		1.	Applicants hereby state that each item of information contained in this								
	information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.										
		2.	Applicants hereby state that no item of information contained in this								
	inform	ation di	sclosure statement was cited in a communication from a foreign patent								
	office in a counterpart foreign patent application, and, to the knowledge of the										
	undersigned after making reasonable inquiry, no item of information contained in the										
	inform	ation di	sclosure statement was known to any individual designated in 37 CFR §								
	1.56 m	ore thar	three months prior to the filing of this information disclosure statement.								
II.	Copies of Listed References										
X	A.	Copies	of all references listed on the attached Form PTO/SB/08 are being supplied								
Copies	s of U.S	. patents	s are not included pursuant to Pre-OG Notice dated July 11, 2003.								
	B.	Copies	of all references listed on the attached Form PTO/SB/08 have already been								
supplie	ed durin	g the pr	osecution of prior application Serial No, filed, from which the								
presen	t applica	ation cla	aims priority pursuant to 35 USC § 120. Therefore, pursuant to 37 CFR §								
1.98(d), copie:	s of the	references listed on the attached Form PTO/SB/08 are not now being								
supplie	ed.										
	C.	This ap	oplication is a PCT national stage application, all references listed on the								
attache	ed Form	PTO/S	B/08 were cited in the international search report, and PCT/DO/EO/903								
indicat	tes that	both the	international search report and the copies of the references listed on the								
attache	ed Form	PTO/S	B/08 are in this national stage file. Therefore, copies of the references								

Concise Statement of Relevance III.

listed on the attached Form PTO/SB/08 are not now being supplied.

All references listed on the attached Form PTO/SB/08 are in the English language, X and, therefore, a concise statement of relevance is not required.

	B.	All references listed on the attached Form PTO/SB/08 are referred to in the
specifi	cation a	and/or were cited in the international search report, and a copy of that search report,
which	indicate	es the degree of relevance found by the Search Authority, is attached.
	The Ex	caminer will note that English language counterparts or Abstracts of non-English
langua	ge refer	ences are also enclosed, as follows:
_		
	C.	All references listed on the attached Form PTO/SB/08 were cited in the search
report	issued b	by the Patent Office, and an English-language version of that search report,
which	indicate	es the degree of relevance found by that Patent Office, is attached.
	D.	This application is a PCT national stage application, all references listed on the
attache	ed Form	PTO/SB/08 were cited in the international search report, and a copy of that search
report,	which	indicates the degree of relevance found by the International Search Authority, is
attache		· ·
	E.	All listed on the attached Form PTO/SB/08 were cited during the prosecution of
the pri	or appli	cation indicated above under II.B.
IV.	Additi	ional Information
	A.	In addition to the references listed on the attached Form PTO/SB/08, Applicants
wish to	o bring	to the attention of the Examiner the following abandoned or co-pending U.S. pater
applica	ations:	
[Pursu	ant to 3	7 CFR § 1.98(a)(2)(iii), copies of these applications are not being submitted.]
_		
	B.	In addition of the references listed on the attached Form PTO/SB/08, Applicants
wish to	o bring	to the attention of the Examiner the information provided on the attached sheet.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS MOLAUOHLIN & MARCUS, P.A.

By.

Kurt G. Briscoe

Attorney for Applicant(s)

Reg. No. 33, 41

875 Third Avenue - 18th Floor New York, New York 10022

Phone: (212) 808-0700

Fax: (212) 808-0844

PTO/SB/08A (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO-1449					Complete if Known						
					Application Number		09/966,522				
O P INFORMATION DISCLOSURE					Filing Date:		September 28, 2001				
STATEMENT BY APPLICANT'S					First Named Inventor		Thomas KRAHN et al				
DCT 2 0 2005 (1)					Art Unit		1641				
	<u> </u>			1	Examiner Name: Po		Pen	Pensee T. Do			
ASPENDEN VALL		of 1			Attorney Docket Number: 10			00717-502 / Bayer 10,139.3 KGB			
			U.	S. PATEN	T DOCUM	IENTS					
Examiner's Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYY		Name of Patentee or Applicant of Cited Document		ant	nnt Pages, Columns, Lines, Where Relevant Passages or Relevant			
·	140.	Number-Kind Code ²						Figures Appear			
	Α	US -									
•	В	US -									
	С	US -									
	D	US -									
	Е	US -									
	F	US -									
			FORE	EIGN PAT	ENT DOC	UMENTS					
Examiner's Initials*	Cite No.	Foreign Patent Document Date MM-DD-Y Country Code ³ -Number ⁴ -Kind Code ⁵			Applicant of Cited Document		ent	1 9 7 7 7	T ⁶		
1111111111	110.										
	G										
	Н	,									
	ı										
	J								-		
	K	NO.	DAT	FNT I ITE	DATTIDE	DOCUMEN	TC				
Examiner's	Cite							ppropriate), title of the item	T ⁶		
Initials*	No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.									
	L	Y. HANSSON, et al; "A rapid method for detection of cellular proliferation using carboxyfluorescein"; Journal of Immunological Methods, 100 (1987); pages 2561-267									
	М										
•	N										

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²see Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴for Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.